Last $11.39 USD
Change Today +0.01 / 0.09%
Volume 2.2K
LZAGY On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
OTC US
OTC US
Singapore
Frankfurt
As of 3:47 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

lonza group ag-unspon adr (LZAGY) Snapshot

Open
$11.33
Previous Close
$11.38
Day High
$11.39
Day Low
$11.30
52 Week High
09/22/14 - $12.55
52 Week Low
04/15/14 - $8.92
Market Cap
6.0B
Average Volume 10 Days
6.5K
EPS TTM
--
Shares Outstanding
529.2M
EX-Date
04/22/14
P/E TM
--
Dividend
--
Dividend Yield
2.16%
Current Stock Chart for LONZA GROUP AG-UNSPON ADR (LZAGY)

Related News

No related news articles were found.

lonza group ag-unspon adr (LZAGY) Related Businessweek News

View More BusinessWeek News

lonza group ag-unspon adr (LZAGY) Details

Lonza Group Ltd. supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. It operates in two segments, Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech segment develops and manufactures active pharmaceutical ingredients (APIs) for drug companies; microbial parenteral API, including antibody fragments, vaccines, cytokines, plasmid DNA, fusion proteins, and PEGylated products; and chemical custom services, such as chemically derived active ingredients, antibody drug conjugates, and cytotoxic and peptide syntheses, as well as biological cellular and gene therapies. This segment also offers cell culture, transfection, and molecular biology tools for lifescience research; media used in the production of therapeutics; endotoxin detection assays; products and services targeting cardiovascular, respiratory, neurological, metabolic, cancer, and other disease research areas; and cell biology solutions to enhance efficiencies in research. This segment serves customers in academic and government institutions, and in biotech and pharmaceutical organizations. The Specialty Ingredients segment offers personal care and preservation products comprising actives for antidandruff shampoos, and natural and organic cosmetic ingredients; vitamin B3 compounds and L-Carnitine, as well as nutritional ingredients used in pharmaceuticals, human energy drinks, and animal feeds; and microbial control solutions, including disinfectants and sanitizers that protect from dangerous and unwanted microbes. This segment also provides custom agricultural manufacturing services to enhance crop yields; sanitizers and other treatment chemicals, as well as feeder systems for drinking water disinfection and surface-water treatments; industrial Solutions, such as preservatives and biocide blends; and products and services that enhance the quality of wood. The company was founded in 1897 and is headquartered in Basel, Switzerland.

9,761 Employees
Last Reported Date: 07/24/14
Founded in 1897

lonza group ag-unspon adr (LZAGY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

lonza group ag-unspon adr (LZAGY) Key Developments

Sunshine Biopharma Signs Agreement with Lonza to Manufacture its Anti Cancer Compound, Adva 27a

Sunshine Biopharma Inc. announced an agreement with Lonza for the manufacture of its anti-cancer drug, Adva-27a. Lonza's expertise and experience in small molecule development and manufacturing of active pharmaceutical ingredients, was an ideal fit for Sunshine's Adva-27a. Lonza's manufacturing capacity ranges from gram quantities for process validation to kilogram amounts for clinical trials and ton quantities for commercialization. Manufacturing will begin at Lonza's Nansha, China facility with the remaining key steps to be conducted in Lonza's high containment cytotoxic facility in Visp, Switzerland.

Lonza Group Ltd Provides Earnings Guidance for 2014

Lonza Group Ltd. provided earnings guidance for 2014. For 2014, the company expects CORE EBIT growth of ~10%, despite the weaker-than-expected Water Treatment results, bringing revenue growth to under 5%. CAPEX will remain below CHF 250 million in 2014. Solid free-cash flow generation enables debt reduction as planned.

Bristol-Myers Squibb and Lonza Expand Manufacturing Agreement

Bristol-Myers Squibb Company and Lonza announced a multi-year expansion of their existing biologics manufacturing agreement. The contract expansion will include the production of commercial quantities of a second Bristol-Myers Squibb biologic medicine at Lonza's mammalian manufacturing facility in Portsmouth, New Hampshire. Financial terms were not disclosed.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LZAGY:US $11.39 USD +0.01

LZAGY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albemarle Corp $60.89 USD +0.41
Clariant AG SFr.16.83 CHF +0.08
Croda International PLC 2,596 GBp -34.00
Symrise AG €50.26 EUR -0.331
Wacker Chemie AG €91.71 EUR -0.022
View Industry Companies
 

Industry Analysis

LZAGY

Industry Average

Valuation LZAGY Industry Range
Price/Earnings 28.4x
Price/Sales 1.4x
Price/Book 2.5x
Price/Cash Flow 28.7x
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LONZA GROUP AG-UNSPON ADR, please visit www.lonza.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.